These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32694863)

  • 1. Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease.
    Diehl AM; Farpour-Lambert NJ; Zhao L; Tilg H
    Nat Metab; 2019 Nov; 1(11):1027-1029. PubMed ID: 32694863
    [No Abstract]   [Full Text] [Related]  

  • 2. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expand SNAP to Reduce Nonalcoholic Fatty Liver Disease in the United States.
    Gundersen C
    J Nutr; 2020 Jan; 150(1):6-7. PubMed ID: 31603197
    [No Abstract]   [Full Text] [Related]  

  • 4. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2019 Mar; 92():82-97. PubMed ID: 30502373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Nonalcoholic Fatty Liver Disease.
    Mitsinikos T; Mrowczynski-Hernandez P; Kohli R
    Pediatr Clin North Am; 2021 Dec; 68(6):1309-1320. PubMed ID: 34736591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease.
    Cai J; Zhang XJ; Li H
    Med Res Rev; 2019 Jan; 39(1):328-348. PubMed ID: 29846945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on nonalcoholic fatty liver disease.
    Provencher DM
    JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening.
    Middleton JP; Wiener RC; Barnes BH; Gurka MJ; DeBoer MD
    Clin Pediatr (Phila); 2014 Dec; 53(14):1318-25. PubMed ID: 24477713
    [No Abstract]   [Full Text] [Related]  

  • 12. The intersection of nonalcoholic fatty liver disease and obesity.
    Woo Baidal JA; Lavine JE
    Sci Transl Med; 2016 Jan; 8(323):323rv1. PubMed ID: 26819197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis.
    Li B; Zhang C; Zhan YT
    Can J Gastroenterol Hepatol; 2018; 2018():2784537. PubMed ID: 30065915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Awareness and Knowledge of Nonalcoholic Fatty Liver Disease Among Office Employees in Beijing, China.
    Zhang W; Chao S; Chen S; Rao H; Huang R; Wei L; Lok AS
    Dig Dis Sci; 2019 Mar; 64(3):708-717. PubMed ID: 30483909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i.
    Pattison RJ; Esteban JP; Sempokuya T; Kewcharoen J; Kalathil S; Kuwada SK
    Hawaii J Health Soc Welf; 2020 Jun; 79(6):180-186. PubMed ID: 32524096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.
    Sayiner M; Koenig A; Henry L; Younossi ZM
    Clin Liver Dis; 2016 May; 20(2):205-14. PubMed ID: 27063264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update.
    Assunção SNF; Sorte NCB; Alves CD; Mendes PSA; Alves CRB; Silva LR
    Nutr Hosp; 2017 Jun; 34(3):727-730. PubMed ID: 28627213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review.
    Hashem A; Khalouf A; Acosta A
    Semin Liver Dis; 2021 Nov; 41(4):435-447. PubMed ID: 34243193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030.
    Goossens N; Bellentani S; Cerny A; Dufour JF; Jornayvaz FR; Mertens J; Moriggia A; Muellhaupt B; Negro F; Razavi H; Semela D; Estes C
    Swiss Med Wkly; 2019 Dec; 149():w20152. PubMed ID: 31846507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease: raising awareness of a looming public health problem.
    Gracen L; Powell EE
    Med J Aust; 2021 Jul; 215(2):75-76. PubMed ID: 34046909
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.